AFP and laryngotracheoesophageal cleft: The HBV-HCC and HCV-HCC patient median plasma levels of AFP, AFU, and HGF were found to be significantly higher than those of the CH and LC patients (Figure 1A, 1B, and 1E), indicating that a high expression of these biomarkers was associated with the progression of liver disease.